Your browser doesn't support javascript.
loading
CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study.
Shock, Anthony; Burkly, Linda; Wakefield, Ian; Peters, Christopher; Garber, Ellen; Ferrant, Janine; Taylor, Frederick R; Su, Lihe; Hsu, Yen-Ming; Hutto, David; Amirkhosravi, Ali; Meyer, Todd; Francis, John; Malcolm, Sarah; Robinson, Martyn; Brown, Derek; Shaw, Stevan; Foulkes, Roland; Lawson, Alastair; Harari, Olivier; Bourne, Timothy; Maloney, Alison; Weir, Neil.
Afiliação
  • Shock A; UCB Pharma, 216 Bath Road, Slough, Berkshire, SL1 4EN, UK. Tony.Shock@ucb.com.
  • Burkly L; Biogen Idec, Inc., 12 Cambridge Center, Cambridge, MA, 02142, USA. linda.burkly@biogenidec.com.
  • Wakefield I; UCB Pharma, 216 Bath Road, Slough, Berkshire, SL1 4EN, UK. wakefield457@btinternet.com.
  • Peters C; UCB Pharma, Braine, Belgium. Christopher.Peters@ucb.com.
  • Garber E; Biogen Idec, Inc., 12 Cambridge Center, Cambridge, MA, 02142, USA. ellen.a.stark@gmail.com.
  • Ferrant J; Biogen Idec, Inc., 12 Cambridge Center, Cambridge, MA, 02142, USA. Janine.Ferrant-Orgettas@biogenidec.com.
  • Taylor FR; Biogen Idec, Inc., 12 Cambridge Center, Cambridge, MA, 02142, USA. jfttpublic@gmail.com.
  • Su L; Biogen Idec, Inc., 12 Cambridge Center, Cambridge, MA, 02142, USA. lhsu@abbiosciences.com.
  • Hsu YM; Present Address: Ab Biosciences Inc., Allston, MA, USA. lhsu@abbiosciences.com.
  • Hutto D; Biogen Idec, Inc., 12 Cambridge Center, Cambridge, MA, 02142, USA. ymhsu@abbiosciences.com.
  • Amirkhosravi A; Present Address: Ab Biosciences Inc., Allston, MA, USA. ymhsu@abbiosciences.com.
  • Meyer T; Biogen Idec, Inc., 12 Cambridge Center, Cambridge, MA, 02142, USA. David.Hutto@crl.com.
  • Francis J; Present Address: Charles River, Wilmington, MA, USA. David.Hutto@crl.com.
  • Malcolm S; Center for Thrombosis Research, Florida Hospital, Orlando, USA. ali.amirkhosravi@flhosp.org.
  • Robinson M; Center for Thrombosis Research, Florida Hospital, Orlando, USA. todd.meyer@flhosp.org.
  • Brown D; Center for Thrombosis Research, Florida Hospital, Orlando, USA. john.francis@flhosp.org.
  • Shaw S; UCB Pharma, 216 Bath Road, Slough, Berkshire, SL1 4EN, UK. Sarah.Malcolm@ucb.com.
  • Foulkes R; UCB Pharma, 216 Bath Road, Slough, Berkshire, SL1 4EN, UK. martyn_robinson@talk21.com.
  • Lawson A; UCB Pharma, 216 Bath Road, Slough, Berkshire, SL1 4EN, UK. dbrown@cheylard.co.uk.
  • Harari O; Present Address: Cheylard Biosciences, Berkshire, UK. dbrown@cheylard.co.uk.
  • Bourne T; UCB Pharma, 216 Bath Road, Slough, Berkshire, SL1 4EN, UK. Stevan.Shaw@ucb.com.
  • Maloney A; UCB Pharma, 216 Bath Road, Slough, Berkshire, SL1 4EN, UK. roly.foulkes@gmx.co.uk.
  • Weir N; Present Address: Hammel Ltd, Buckinghamshire, UK. roly.foulkes@gmx.co.uk.
Arthritis Res Ther ; 17: 234, 2015 Sep 03.
Article em En | MEDLINE | ID: mdl-26335795
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Trombose / Ligante de CD40 / Imunidade Humoral / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Trombose / Ligante de CD40 / Imunidade Humoral / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article